MX2021004779A - Anticuerpos cd47 novedosos y metodos para usarlos. - Google Patents

Anticuerpos cd47 novedosos y metodos para usarlos.

Info

Publication number
MX2021004779A
MX2021004779A MX2021004779A MX2021004779A MX2021004779A MX 2021004779 A MX2021004779 A MX 2021004779A MX 2021004779 A MX2021004779 A MX 2021004779A MX 2021004779 A MX2021004779 A MX 2021004779A MX 2021004779 A MX2021004779 A MX 2021004779A
Authority
MX
Mexico
Prior art keywords
antibodies
novel
methods
same
glycosylation
Prior art date
Application number
MX2021004779A
Other languages
English (en)
Inventor
Wei Cao
Lei Fang
Zhengyi Wang
Bingshi Guo
Original Assignee
I Mab Biopharma Us Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by I Mab Biopharma Us Ltd filed Critical I Mab Biopharma Us Ltd
Publication of MX2021004779A publication Critical patent/MX2021004779A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
    • C12Y305/01052—Peptide-N4-(N-acetyl-beta-glucosaminyl)asparagine amidase (3.5.1.52), i.e. glycopeptidase

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Entre otros, la presente invención proporciona composiciones farmacéuticas cada una que comprenden un agente de glicosilacion, un anticuerpo que enlaza CD47 humano, y un portador farmacéuticamente aceptable. También se proporcionan anticuerpos CD47 novedosos que enlazan a CD47 humano, en donde los anticuerpos enlazan a por lo menos un epitopo que está en uno de los sitios de glicosilacion de la proteína CD47 de los glóbulos rojos (por ejemplo, por lo menos un sitio de glicosilacion cerca de los residuos de epitopo Gln31 y Thr34 en CD47).
MX2021004779A 2018-10-31 2019-10-31 Anticuerpos cd47 novedosos y metodos para usarlos. MX2021004779A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2018113126 2018-10-31
PCT/CN2019/114662 WO2020088580A1 (en) 2018-10-31 2019-10-31 Novel cd47 antibodies and methods of using same

Publications (1)

Publication Number Publication Date
MX2021004779A true MX2021004779A (es) 2021-06-08

Family

ID=70462951

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021004779A MX2021004779A (es) 2018-10-31 2019-10-31 Anticuerpos cd47 novedosos y metodos para usarlos.

Country Status (12)

Country Link
US (1) US20210269522A1 (es)
EP (1) EP3826676A4 (es)
JP (1) JP2022500357A (es)
KR (1) KR20210098427A (es)
CN (1) CN112105386A (es)
AU (1) AU2019370754A1 (es)
BR (1) BR112021008332A2 (es)
CA (1) CA3107369A1 (es)
IL (1) IL280225A (es)
MX (1) MX2021004779A (es)
SG (1) SG11202104301SA (es)
WO (1) WO2020088580A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3044097A1 (en) * 2017-11-10 2019-05-16 I-Mab Fusion proteins containing cd47 antibodies and cytokines
CN110582515A (zh) * 2018-11-12 2019-12-17 天境生物科技(上海)有限公司 包含cd47抗体和细胞因子的融合蛋白
JP2023546277A (ja) * 2020-10-14 2023-11-01 アイ‐マブ バイオファーマ シーオー．， エルティーディー． 新規の抗ｃｄ４７抗体及びその使用
TW202302145A (zh) 2021-04-14 2023-01-16 美商基利科學股份有限公司 ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
WO2023165615A1 (en) * 2022-03-04 2023-09-07 I-Mab Biopharma Co., Ltd. Combination therapies comprising a kras inhibitor for the treatment of cancer
WO2023183817A1 (en) 2022-03-24 2023-09-28 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
TW202345901A (zh) 2022-04-05 2023-12-01 美商基利科學股份有限公司 用於治療結腸直腸癌之組合療法
WO2024064668A1 (en) 2022-09-21 2024-03-28 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050100964A1 (en) * 2003-11-11 2005-05-12 George Jackowski Diagnostic methods for congestive heart failure
NZ628314A (en) * 2012-02-06 2017-01-27 Inhibrx Lp Cd47 antibodies and methods of use thereof
SG11201506132PA (en) * 2013-02-06 2015-09-29 Inhibrx Llc Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof
JP6850255B2 (ja) * 2014-12-30 2021-03-31 セルジーン コーポレイション 抗−ｃｄ４７抗体及びその使用
CA2978594A1 (en) * 2015-03-04 2016-09-09 Sorrento Therapeutics, Inc. Antibody therapeutics that bind cd47
HRP20220069T1 (hr) * 2015-08-10 2022-04-15 Osaka University Antitijelo
BR112018014028A2 (pt) * 2016-01-11 2019-02-05 Forty Seven Inc anticorpos monoclonais anti-cd47 humanizados, de camundongo ou quimérico
CN107459578B (zh) * 2016-05-31 2021-11-26 泰州迈博太科药业有限公司 一种靶向cd47与pd-l1的双功能融合蛋白
CN108738313B (zh) * 2016-10-20 2022-12-30 天境生物科技(上海)有限公司 新的cd47单克隆抗体及其应用
CN108503708B (zh) * 2017-09-01 2021-07-30 北京智仁美博生物科技有限公司 抗人cd47抗体及其用途

Also Published As

Publication number Publication date
US20210269522A1 (en) 2021-09-02
JP2022500357A (ja) 2022-01-04
EP3826676A4 (en) 2022-05-04
KR20210098427A (ko) 2021-08-10
EP3826676A1 (en) 2021-06-02
BR112021008332A2 (pt) 2021-08-03
CN112105386A (zh) 2020-12-18
CA3107369A1 (en) 2020-05-07
WO2020088580A1 (en) 2020-05-07
SG11202104301SA (en) 2021-05-28
AU2019370754A1 (en) 2021-02-04
IL280225A (en) 2021-03-01

Similar Documents

Publication Publication Date Title
MX2021004779A (es) Anticuerpos cd47 novedosos y metodos para usarlos.
MX2021010531A (es) Proteina de fusion bifuncional y uso farmaceutico de la misma.
WO2021260209A3 (en) Ccr8 antibodies and uses thereof
MX2019004692A (es) Anticuerpos 4-1bb anti-humano y usos de los mismos.
ATE471946T1 (de) Humanisierter antikörper (h14.18) des maus antikörpers 14.18, der gd2 bindet und seine fusion mit il-2
BR112018002844A2 (pt) receptores de antígeno quimérico à base de anticorpos de domínio único e métodos de uso dos mesmos
MY196756A (en) Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
WO2019160751A3 (en) Methods for treating cancer with anti-pd-1 antibodies
UA116772C2 (uk) Виділене моноклональне антитіло або його імунологічно-активний фрагмент, що зв'язується з cd47
NO20081124L (no) Anti-CD 3 antistoff-formuleringer
WO2019060750A3 (en) A33 antibody compositions and methods of using the same in radioimmunotherapy
PE20121702A1 (es) Proteinas de enlace cd127
SG10201803473WA (en) Methods for enhancing immunosuppressive therapy by multiple administration of alpha beta tcr-binding polypeptide
WO2019204462A3 (en) Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs
EA202192294A1 (ru) Антитела к trem2 и способы их применения
MX2022007231A (es) Anticuerpos anti-mertk y metodos de uso de los mismos.
PH12020551661A1 (en) Anti-pd-l1 antibody and use thereof
MX2021005085A (es) Formulacion de anticuerpo.
EA202193309A1 (ru) Конъюгаты антитело к тканевому фактору-лекарственное средство и связанные способы
MX2020008730A (es) Regímenes de dosificación de anticuerpo b7-h4.
MX2021004226A (es) Terapia combinada contra el cáncer.
WO2021076554A8 (en) Antibodies targeting flt3 and use thereof
JP2020502198A5 (es)
MX2021010254A (es) Conjugados de anticuerpo-farmaco que comprenden anticuerpos anti-tm4sf1 y metodos de uso de los mismos.
ATE444310T1 (de) Antiidiotypische antikörper die hiv-1 neutralisierende antikörper induzieren